Vanguard Asset Management
CTMX icon

Vanguard Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Vanguard Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Hold
122,893
– – ﹤0.01% 2215
2026
Q1 		$578K Buy
+122,893
New +$624K ﹤0.01% 2029

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EC
Elmind Capital New York $398M AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Asset Management's CTMX Position: Q2 2026 in Review

Vanguard Asset Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 122,893 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Vanguard Asset Management first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $578K in Q1 2026. 161 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Vanguard Asset Management held 122,893 shares of CytomX Therapeutics worth $461K as of Q2 2026.
  • Vanguard Asset Management left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2215 holding.
  • Vanguard Asset Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's CytomX Therapeutics position peaked at $578K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.